Bentley Pharmaceuticals Reports Record Revenues in Second Quarter
of 2004 - Conference call and webcast to be held today at 10:00
A.M. (EDT) - EXETER, N.H., July 28 /PRNewswire-FirstCall/ --
Bentley Pharmaceuticals, Inc. (NYSE:BNT), a technology-based
specialty pharmaceutical and drug delivery company with a growing
branded and generic product line in Europe, today announced
financial results for the second quarter and six months ended June
30, 2004. Total revenues for the 2004 second quarter increased
10.2% to a record $18.5 million from $16.8 million in the
prior-year's second quarter. At constant exchange rates, revenues
were up 4.0%. Net product sales grew 4.9%, to $17.4 million from
$16.6 million in last year's second quarter; however, net product
sales remained consistent when expressed in constant currency.
Licensing and collaboration revenues increased significantly to
$1.1 million from $158,000 in the comparable year-ago quarter. In
addition to the favorable impact of exchange rates, second quarter
revenues reflected: -- Continued volume growth in Spain, partially
offsetting price reductions announced last year; -- Increased
royalties from sales of Testim(R), the first marketed product to
incorporate Bentley's CPE-215 drug delivery technology; --
Continued rapid growth in pharmaceutical product sales outside
Spain. Factors which partially offset growth in the second quarter
included: -- The continued effect of pharmaceutical pricing
regulations implemented in December 2003 in Spain, which impacted
several product lines; -- Elevated levels of product returns in
April and May 2004 (totaling approximately $500,000) of older
pharmaceutical products associated with the implementation of
pharmaceutical pricing regulations in December of 2003. Sales
outside of Spain continued to grow strongly, rising 60% to $3.8
million from $2.3 million in last year's second quarter. As a
percentage of total revenues, sales outside of Spain grew to 20%
from 14% in the year ago quarter, driven by license and supply
agreements with more than 25 entities, primarily in Europe. The
Company expects sales outside of Spain to continue to be a major
contributor to its growth throughout 2004 and beyond. Second
quarter operating income totaled $2.6 million compared to $3.3
million a year earlier, reflecting higher operating expenses due to
increased costs in the current year necessary to support current
and future growth. Net income for the 2004 second quarter was $1.5
million, or $0.07 per diluted share, compared to $1.5 million, or
$0.07 per diluted share, in the year-ago period. Diluted shares
outstanding increased 9% from the second quarter of 2003, primarily
as a result of the exercise of the Company's Class B Redeemable
Warrants. Net income was positively affected by a reversal of
previously accrued expenses related to pharmaceutical tax
assessments in Spain which are no longer considered due or payable
as a result of changes in Spain. The Company has recorded a pretax
benefit totaling $1.47 million ($954,000 after taxes) as a
component of other income and expenses. These assessments were
accrued to be paid to the Spanish government as a vehicle to help
reduce the impact of the rising health care costs in Spain. Due to
recent changes in the pharmaceutical industry in Spain and a change
in the Spanish political environment, these liabilities no longer
exist. Accordingly, these amounts have been reversed during the
quarter ended June 30, 2004. In addition, a tax audit of the
Company's Spanish subsidiary for tax years 1998 through 2000 has
been completed by the Spanish tax authorities during the quarter
ended June 30, 2004. As a result of this audit, the Company has
been assessed an additional tax liability of approximately
$600,000, which has been recorded as a component of the provision
for income taxes, and related interest and penalties totaling
approximately $190,000, which have been recorded as a component of
other income and expenses. James R. Murphy, President and CEO,
stated, "Our revenues for the second quarter were primarily driven
by increases in sales of Paroxetine and Codeisan within Spain, the
growth of our sales outside of Spain and a significant increase in
royalties from sales of Auxilium's Testim. The performance of our
Spanish operations reflects continued market share gains, which
were offset by the pharmaceutical pricing regulations effected in
December 2003." Revenues for the six months ended June 30, 2004
grew 12.7% (1.6% at constant currency) to $35.8 million from $31.7
million in the same period of the prior year, in spite of the lower
prices. Operating income totaled $4.3 million compared to $6.0
million in the six months ended June 30, 2003, reflecting the
previously disclosed product price reductions, product returns and
higher operating expenses in 2004. Net income for the first six
months of 2004 totaled $2.3 million, or $0.10 per diluted share,
compared to $3.1 million, or $0.15 per diluted share in the year
ago period. Diluted shares outstanding increased 11% from the 2003
six-month period primarily as a result of the exercise of the
Company's Class B Redeemable Warrants. Mr. Murphy continued, "We
expect to continue to increase future sales volume through our
pipeline of approximately 100 products, consisting of roughly 20
chemical entities. We are pleased with the significant increase in
our sales outside of Spain and expect that part of our business to
continue to grow and become a larger component of our
pharmaceutical product sales. Additionally, to further enhance our
productivity, we have implemented several initiatives directed at
cost reductions and achieving manufacturing efficiencies. We will
continue to focus on acquiring, developing and launching new
products that will further enhance our product mix," Mr. Murphy
added. Michael D. Price, Vice President and Chief Financial
Officer, commented, "We expect gross margins to continue to move
back toward our historic 54% - 56% range. Future gross margins and
profits should gradually benefit from the launch of new
pharmaceutical products, increased efficiencies in our
manufacturing processes and economies of scale. "We continue to
have a strong balance sheet, with $36 million in cash and
investments, and a healthy current ratio of approximately 2.5 to 1.
Our total assets are approximately $110 million with essentially no
long-term debt, putting us in an excellent position to invest in
our growth as quality opportunities arise. We believe that our
impressive and growing product portfolio and our highly efficient
manufacturing processes will drive continued sales growth both
inside and outside of Spain, as well as productivity improvements
which garner added operating leverage." Mr. Murphy concluded, "We
are well positioned for continued financial and strategic progress,
and reaffirm our full year 2004 expectations for revenues in the
range of $70 million to $80 million." Significant components of
Bentley's revenues for the three months ended June 30, 2004 and
2003 are as follows: For the Three Months Ended June 30, 2004:
Sales Within Spain % of Branded Generic Contract Other Total
Product Line Products Products Manufacturing Revenues Total
Revenues Omeprazole $647 $3,204 $ -- $ -- $3,851 21% Simvastatin
354 868 -- -- 1,222 7% Enalapril 893 327 -- -- 1,220 7% Paroxetine
228 765 -- -- 993 5% Codeisan 608 -- -- -- 608 3% All other
products 1,535 1,646 -- 264 3,445 19% Contract manufacturing -- --
2,304 -- 2,304 12% Sales outside of Spain -- -- -- 3,764 3,764 20%
Licensing and collaborations -- -- -- 1,063 1,063 6% Total Revenues
$4,265 $6,810 $2,304 $5,091 $18,470 100% % of Total Revenues 23%
37% 12% 28% 100% For the Three Months Ended June 30, 2003: Sales
Within Spain % of Branded Generic Contract Other Total Product Line
Products Products Manufacturing Revenues Total Revenues Omeprazole
$1,694 $3,431 $ -- $ -- $5,125 31% Simvastatin 588 1,128 -- --
1,716 10% Enalapril 743 460 -- -- 1,203 7% Paroxetine -- 207 -- --
207 1% Codeisan 524 -- -- -- 524 3% All other products 1,236 1,629
-- -- 2,865 17% Contract manufacturing -- -- 2,607 -- 2,607 16%
Sales outside of Spain -- -- -- 2,349 2,349 14% Licensing and
collaborations -- -- -- 158 158 1% Total Revenues $4,785 $6,855
$2,607 $2,507 $16,754 100% % of Total Revenues 28% 41% 16% 15% 100%
NOTICE OF CONFERENCE CALL The Company will host a conference call
to discuss these results and the outlook for the remainder of 2004
today at 10:00 A.M. EDT. To participate in the call, please dial
(800) 399-3081 approximately 10 minutes prior to the scheduled
start time and give the password "BENTLEY". International
participants may dial (706) 679-0718; the password is the same. The
conference call will also be broadcast live on the Internet and may
be accessed via the Company's website,
http://www.bentleypharm.com/. A replay of the conference call will
be available through August 4, 2004. Listeners may access the
replay via the Company's website, http://www.bentleypharm.com/, or
by dialing (800) 642-1687 from within the U.S. and Canada and using
access code 8816411. A replay of the conference call from
international locations may be accessed by dialing (706) 645-9291
using the same access code. Copies of Bentley Pharmaceuticals'
press releases and other information may be obtained through
Bentley's web site at http://www.bentleypharm.com/. Safe Harbor
Statement under the Private Securities Litigation Reform Act of
1995: This press release contains forward looking statements,
including without limitation, statements regarding our anticipated
2004 revenues, our 2004 operating performance including gross
margin and profit expectations, anticipated sources of future
revenue, the prospects for growth of our business outside of Spain,
and expectations for launching new products. These forward-looking
statements are subject to a number of risks and uncertainties that
could cause actual results to differ materially from future results
expressed or implied by such statements. Factors that may cause
such differences include, but are not limited to risks associated
with expanding generic and branded drug operations, changes in
third-party reimbursement and government mandates which impact
pharmaceutical pricing, development and commercialization of new
products, our relationships with our strategic partners, clinical
trials, regulatory approval processes, the unpredictability of
patent protection, technological changes, the effects of economic
conditions, risks associated with international operations,
competition from other manufacturers of generic, and proprietary
pharmaceuticals and other uncertainties detailed in Bentley's most
recent Annual Report on Form 10-K and its other subsequent periodic
reports filed with the Securities and Exchange Commission. Bentley
cautions investors not to place undue reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this document, and Bentley
undertakes no obligation to update or revise the statements, except
as may be required by law. - TABLES TO FOLLOW - BENTLEY
PHARMACEUTICALS, INC. AND SUBSIDIARIES CONSOLIDATED INCOME
STATEMENTS (in thousands, except per share data) For the Three
Months For the Six Months Ended June 30, Ended June 30, 2004 2003
2004 2003 Revenues: Net product sales $17,407 $16,596 $34,013
$30,831 Licensing and collaboration revenues 1,063 158 1,759 911
Total revenues 18,470 16,754 35,772 31,742 Cost of net product
sales 8,396 6,819 16,592 12,940 Gross profit 10,074 9,935 19,180
18,802 Operating expenses: Selling and marketing 3,851 3,626 7,721
6,979 General and administrative 2,287 1,786 4,451 3,345 Research
and development 946 879 1,941 1,897 Depreciation and amortization
407 328 813 611 Total operating expenses 7,491 6,619 14,926 12,832
Income from operations 2,583 3,316 4,254 5,970 Other income
(expenses): Interest income 132 82 242 165 Interest expense (58)
(64) (111) (118) Other, net 1,274 -- 1,274 -- Income before income
taxes 3,931 3,334 5,659 6,017 Provision for income taxes 2,441
1,805 3,361 2,956 Net income $1,490 $1,529 $2,298 $3,061 Net income
per common share: Basic $0.07 $0.09 $0.11 $0.17 Diluted $0.07 $0.07
$0.10 $0.15 Weighted average common shares outstanding: Basic
20,644 17,534 20,620 17,495 Diluted 22,800 20,878 22,787 20,617
BENTLEY PHARMACEUTICALS, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE
SHEETS (in thousands, except per share data) June 30, December 31,
2004 2003 ASSETS Current assets: Cash and cash equivalents $35,743
$39,393 Marketable securities 465 1,252 Receivables, net 23,772
18,036 Inventories, net 9,605 7,106 Deferred taxes 237 213 Prepaid
expenses and other 1,857 899 Total current assets 71,679 66,899
Non-current assets: Fixed assets, net 23,057 18,566 Drug licenses
and related costs, net 13,889 13,818 Restricted cash 1,000 1,000
Other 162 180 Total non-current assets 38,108 33,564 $109,787
$100,463 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities:
Accounts payable $14,949 $10,154 Accrued expenses 8,355 7,103
Short-term borrowings 1,871 1,915 Current portion of long-term debt
-- 70 Deferred income 3,167 1,956 Total current liabilities 28,342
21,198 Non-current liabilities: Deferred taxes 2,353 2,555
Long-term debt 360 369 Other 75 176 Total non-current liabilities
2,788 3,100 Commitments and contingencies Stockholders' equity:
Preferred stock, $1.00 par value, authorized 2,000 shares, issued
and outstanding, none -- -- Common stock, $.02 par value,
authorized 100,000 shares, issued and outstanding, 20,787 and
20,573 shares 416 412 Stock purchase warrants (to purchase 400 and
420 shares of common stock) 333 333 Additional paid-in capital
138,578 136,850 Accumulated deficit (64,301) (66,599) Accumulated
other comprehensive income 3,631 5,169 Total stockholders' equity
78,657 76,165 $109,787 $100,463 DATASOURCE: Bentley
Pharmaceuticals, Inc. CONTACT: Michael D. Price, Vice President,
Chief Financial Officer of Bentley Pharmaceuticals, Inc.,
+1-603-658-6100; or Investors: Jonathan Birt, Lanie Marcus, or Sean
Leous, all of Financial Dynamics, +1-212-850-5600, for Bentley
Pharmaceuticals, Inc. Web site: http:/www.bentleypharm.com
Copyright